The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
18 years of age or older,
with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.
without social security
No access to tumor block
In the health centers, patients were identified in two ways: 1. via diagnoses obtained in the anatomopathology departments of each investigating center 2. via multidisciplinary consultation meetings on primary hepatic tumours/digestive oncology at each investigating center. Patients with a diagnosis of rare primary hepatic cancers diagnosed on or after 01/01/2018 may be included, whether alive or deceased at the time of registration in the CAPRIH cohort.
Cohort
Other
Not listed
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Recurrence-free survival (for non-metastatic patients)
Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news
Progression-free survival (for metastatic patients)
Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.
Overall survival
Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.
Click on the lead sponsor to view all of their trials.
Federation Francophone de Cancerologie Digestive
Lead sponsor
Société Nationale Française de Gastroentérologie
Collaborator
